Christopher M Yea - KalVista Pharmaceuticals

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 16 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

NEW ENGLAND JOURNAL OF MEDICINEno. 1 (2024): 32-43

引用0浏览0WOS引用

Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: a Systematic Review

Hilary J. Longhurst,Mauro Cancian,Vesna Grivcheva-Panovska, Majed Koleilat, Markus Magerl,Sinisa Savic,Marcin Stobiecki,Raffi Tachdjian, Bridget Healy,Christopher M. Yea,Paul K. Audhya, Laurence Bouillet

Clinical reviews in allergy & immunology (2024)

引用0浏览0WOS引用

Evaluation of Patient-Reported Outcome Measures for On-Demand Treatment of Hereditary Angioedema Attacks and Design of KONFIDENT, a Phase 3 Trial of Sebetralstat

Danny M. Cohn,Emel Aygoeren-Puersuen,Jonathan A. Bernstein,Henriette Farkas,William R. Lumry,Marcus Maurer,Andrea Zanichelli,Matthew Iverson,James Hao,Michael D. Smith,Christopher M. Yea,Paul K. Audhya,Marc A. Riedl

Clinical and translational allergyno. 9 (2023): e12288-e12288

引用0浏览0WOS引用

KVD900, an Oral On-Demand Treatment for Hereditary Angioedema: Phase 1 Study Results

Andreas Maetzel,Michael D. Smith,Edward J. Duckworth,Sally L. Hampton,Gian Marco De Donatis,Nivetha Murugesan,Louise J. Rushbrooke,Lily Li,Danielle Francombe,Edward P. Feener,Christopher M. Yea

Journal of Allergy and Clinical Immunology（2022）

引用9浏览0WOS引用

Agreement between improvements in patient global impression of change and other measures of improvement and attack resolution observed in a phase 2 trial with KVD900 in patients with hereditary angioedema

Paul K. Audhya,Michael D. Smith, Peter Williams,Christopher M. Yea,Danny M. Cohn

ALLERGY AND ASTHMA PROCEEDINGS（2022）

引用0浏览0引用

Pharmacological Suppression of the Kallikrein Kinin System with KVD900: an Orally Available Plasma Kallikrein Inhibitor for the On‐demand Treatment of Hereditary Angioedema

Edward J. Duckworth,Nivetha Murugesan,Lily Li,Louise J. Rushbrooke, Daniel K. Lee,Gian Marco De Donatis,Andreas Maetzel,Christopher M. Yea,Sally L. Hampton,Edward P. Feener

Clinical & Experimental Allergy（2022）

引用6浏览0WOS引用

Oral KVD900 provides rapid inhibition of plasma kallikrein and fast improvement in attack symptoms in patients with hereditary angioedema

Michael D. Smith,Edward J. Duckworth,Sally L. Hampton,Christopher M. Yea,Paul Audhya,Edward P. Feener

ALLERGY AND ASTHMA PROCEEDINGSno. 6 (2022): 563-563

引用0浏览0引用

Phase 3 trial design for KVD900, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema attacks

William R. Lumry,Emel Aygoren-Pursun,Andrea Zanichelli,Danny M. Cohn,Henriette Farkas,Jonathan A. Bernstein,Paul K. Audhya,Michael D. Smith,Christopher M. Yea,Marc A. Riedl,Marcus Maurer

ALLERGY AND ASTHMA PROCEEDINGSno. 6 (2022): 563-563

引用0浏览0引用

KVD900 As a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic Results from a Phase 1 Single Ascending Dose Study

Sally L. Hampton,Gian Marco De Donatis,Nivetha I. Murugesan,Louise J. Rushbrooke,Lily Li,Edward Duckworth,Michael D. Smith, Rachel M. Morten,Andreas Maetzel,Christopher M. Yea,Edward P. Feener

The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The jo...（2019）

引用7浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn